Covid-19: a 3rd dose of Pfizer / BioNTech vaccine 95.6% effective

“We believe that boosters have a critical role to play in addressing the current threat of this pandemic,” said Albert Bourla, Chairman and CEO of Pfizer.

Booster doses of the Pfizer / BioNTech vaccine against Covid-19, also called “booster” doses, “demonstrate a relative vaccine efficacy of 95.6%” against symptomatic forms of the disease, according to a study carried out by the two laboratories, the conclusions of which were published in a press release Thursday. And this during a period when the “Delta variant was the prevalent strain”.

“We believe that boosters have a critical role to play in addressing the current threat of this pandemic,” said Albert Bourla, Chairman and CEO of Pfizer. “We look forward to sharing this data with health authorities and working together to determine how it can be used to support the deployment of booster doses around the world.”

The phase 3 clinical trial, carried out on “10,000 people over 16 years of age”, shows “a relative efficacy of 95.6%” and “a favorable safety profile”, according to the company’s press release.

>>> MORE INFO TO COME ON BFMTV.COM

Leave a Comment